The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
about
Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and CancerMolecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesGlypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinomaAdvances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinActivation of the transcription factor GLI1 by WNT signaling underlies the role of SULFATASE 2 as a regulator of tissue regenerationGPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growthPrognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysisActivation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma.Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival.Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.Heparan sulfate proteoglycans undergo differential expression alterations in right sided colorectal cancer, depending on their metastatic character.SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.Novel therapeutic targets in the brain tumor microenvironmentWnt3a: functions and implications in cancer.Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.Role of heparan sulfatases in ovarian and breast cancer.Oncogenic Wnt3a expression as an estimable prognostic marker for hepatocellular carcinoma.Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate.The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signalingCharacterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.Boning up on glypicans--opportunities for new insights into bone biology.The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.Glycosylation alterations in lung and brain cancer.Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma.Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma.Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP.Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma.Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma.New tumor suppressor microRNAs target glypican-3 in human liver cancer.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.Overexpression of HLA-DR is associated with prognosis of glioma patients.Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions.Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
P2860
Q26740617-1E6A22FF-B269-4445-9F3C-ED0B321DA2D9Q26745338-5A64B7B7-4972-4428-B13E-6988D15C948FQ26772321-1945AC4B-A31C-422B-A7C2-6EA2BBF0A6ECQ27015134-98D0276E-1F96-4AA2-8E46-E34C1E976CD2Q28512564-27895BE6-F013-4B1E-850C-F6B29CA43140Q34000565-A3F02D57-940A-4DB3-9F30-0388A7BBC689Q35096817-2E4A2600-F6EE-4796-A3D2-29F06FA70405Q35224629-1FA4B134-B2FF-4646-81CA-2DC9CEDD5186Q35341540-A7A0B284-4D4B-4BEA-8A95-8CFA31863138Q35659513-FE0B2333-1F89-45C7-93D8-339814D2C218Q35738941-F3139183-8C2C-4CA2-B2CA-0B6AED151A56Q35813723-1A2CB555-FFC7-4BBB-BC04-C2B46435AA9CQ35840419-6BBC3E3F-4A2D-45CC-86EE-B5FEDC49D293Q35925048-CB166999-908D-446A-8F89-A0B359949128Q36071884-F108E37B-6A98-4900-8C5B-AC81F0AD97D3Q36121065-965AF9A9-274F-46D0-BE40-F45209F6CCACQ36245519-EA884B0C-B49C-4997-AEF4-4092EA7C521FQ36562888-67CDDF25-66E6-4F8A-956F-6A19B9AE32CFQ36747844-31225281-E9EF-4CE5-A173-2F7FB1C544D0Q36906823-4091064F-FF79-4858-85BB-BBE3B669947CQ37467900-11CB4AD2-CC69-4B55-85CB-D8B85FE03A7BQ37685728-9E0E337A-282D-4B44-8FFF-1551612F5BF6Q37966605-FA112466-3ED8-480F-A6B5-2D3DB001305CQ38072394-2F85CB02-EDA7-4D42-B5C7-FECF1D761651Q38238094-0EAA57BF-9825-46B3-A52E-DB943F6DB7E3Q38366332-3B43F34B-2869-4FBD-9D19-12E818C12C79Q38492203-17A90B33-2B68-4DD5-9E8D-338C8D9158C3Q38806342-4BF3BBBE-2791-456D-87D9-98293E96FE6FQ39260842-FFAC4575-F417-4734-9E95-200EE670AA01Q39378285-6F577227-7C81-4380-B0E0-642281BF075DQ39637442-BCA735FB-E0D0-4351-ADDB-7435230DBDD9Q40311544-56AA290A-182F-4A1A-B0EE-8951BEF117C7Q40463354-55EC8916-C3AE-4255-B51B-C0EA60A7BF6EQ41093562-6BD23612-0576-4CF6-AEF8-E1CBAFCF2EC1Q41138780-E1959FB8-AEF5-4E5C-BD5C-F464820F5653Q41570185-73D37A26-164F-4338-941F-112D25ED095FQ42366558-ACD2493B-D7A4-4E83-A48E-F503B13986B2Q46184952-A99AE1B6-F1A1-4331-97EF-012306382434Q47378147-46B1AD21-D21E-4F39-ABF7-BB5624220090Q50076590-B08A567D-09C5-4F3F-A402-4462102BA895
P2860
The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@en
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@nl
type
label
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@en
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@nl
prefLabel
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@en
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@nl
P2093
P2860
P356
P1433
P1476
The oncogenic effect of sulfat ...... an 3-dependent Wnt activation.
@en
P2093
Abdirashid M Shire
Abdul M Oseini
Alex A Adjei
Catherine D Moser
Chunling Hu
Chunrong Yu
Hajime Isomoto
Ikuo Nakamura
Ileana Aderca
P2860
P304
P356
10.1002/HEP.23848
P407
P577
2010-11-01T00:00:00Z